Related Experiment Video
Updated: Mar 20, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Masupirdine, a Selective Serotonin 5‑HT6 Receptor Antagonist for Alzheimer's Disease
Mireia Toledano-Pinedo1, Isabel Iriepa2,3, M Mercedes Rodríguez-Fernández4
1Institute of General Organic Chemistry (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
None:
Masupirdine is an oral, small, and safe molecule, readily available by a robust, two-step synthetic scheme, showing a potent, selective serotonin 5-HT6 receptor antagonist profile, pro-cognitive effects in various behavioral animal models in Phase 3 clinical trials for the treatment of agitation in patients with Alzheimer's dementia.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting Neurotransmitter Release or Uptake
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

